What to Watch in the Day Ahead - Friday, February 3

Feb 1 (Reuters) - Medicure Inc: * MEDICURE ANNOUNCES RESIGNATION OF BOARD MEMBER AND GRANT OF STOCK OPTIONS Source text for Eikon: Further company coverage:

Feb 1 (Reuters) - Numinus Wellness Inc: * NUMINUS RECEIVES CLINICAL TRIAL APPLICATION APPROVAL FROM HEALTH CANADA FOR EXPERIENTIAL PSYCHEDELIC-ASSISTED THERAPY TRAINING USING PSILOCYBE CUBENSIS TEA

Feb 1 (Reuters) - The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy. THE GLOBE AND MAIL - The Alberta

Jan 30 (Reuters) - FSD Pharma Inc: * RECRUITING UNDERWAY IN FSD PHARMA’S PHASE 2 TRIAL OF FSD-PEA (FSD201) FOR THE TREATMENT OF CHRONIC PAIN ASSOCIATED WITH IDIOPATHIC MCAS (MCAD) Source text for

* ESSA Pharma Inc is expected to show no change in quarterly revenue when it reports results on February 1 (estimated). * * ​Refinitiv's mean analyst estimate for ESSA Pharma Inc is for a loss of 23

30 January 2023 12:42 p.m. All figures in US dollars. ESSA Pharma Inc is expected to show a decrease in its fourth quarter earnings to -23 cents​ per share according to the mean Refinitiv estimate

Jan 30 (Reuters) - Microbix Biosystems Inc: * MICROBIX LAUNCHES QAP TO SUPPORT “MONKEYPOX” TESTING Source text for Eikon: Further company coverage:

Jan 30 (Reuters) - Aptose Biosciences Inc: * APTOSE INITIATES DOSING OF TUSPETINIB IN APTIVATE EXPANSION TRIAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA * APTOSE BIOSCIENCES INC-ANOTHER CLINICAL

* High Tide Inc is expected to show a rise in quarterly revenue when it reports results on January 30. * The Calgary Alberta-based company is expected to report a 87.3% increase in revenue to C$100.9

Jan 27 (Reuters) - XORTX Therapeutics Inc: * XORTX THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING Further company coverage: